A randomized, double-blind, active comparator study to evaluate the antihypertensive efficacy and safety of losartan/HCTZ [hydrochlorothiazide] combination as compared to losartan monotherapy in pediatric patients with essential hypertension.

Trial Profile

A randomized, double-blind, active comparator study to evaluate the antihypertensive efficacy and safety of losartan/HCTZ [hydrochlorothiazide] combination as compared to losartan monotherapy in pediatric patients with essential hypertension.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Losartan/hydrochlorothiazide (Primary) ; Losartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 09 Feb 2012 Planned number of patients changed from 300 to 600 as reported by ClinicalTrials.gov.
    • 03 May 2010 New source identified and integrated (United Kingdome Clinical Research Network record 3828).
    • 27 Dec 2007 The number of treatment arms changed from 2 to 4.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top